Biogen to pay out $1.25 billion to settle Tecfidera patent dispute
Danish biopharma a company Forward Pharma (Nasdaq: FWP) has entered into a binding agreement with two wholly-owned subsidiaries of Biogen (Nasdaq: BIIB) on a settlement and license agreement, with the news sending Forward’s sharing surged 61% to $29.59 in premarket trading on Tuesday.
US biotech major Biogen will pay Forward a non-refundable cash fee of $1.25 billion in connection with the execution and delivery of the license agreement. Under certain circumstances, Biogen will also be obligated to pay Forward royalties of up to 10%-20% of net sales of Biogen products, including Tecfidera (dimethyl fumarate), approved for the treatment of multiple sclerosis that are covered by a Forward patent and have dimethyl fumarate (DMF) as an active pharmaceutical ingredient.
Tecfidera generated sales of $1.03 billion in the third quarter of 2016, accounting for about a third of Biogen's sales in the period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze